Bryan Corporation Announces FDA
Selected Abstract
Bryan Corporation Announces FDA Approval of Sterile Talc Powder for the Treatment of Malignant Pleural Effusion Pleurodesis Via Chest Tube Administration.
WOBURN, Mass., Dec. 16 /PRNewswire/ -- Bryan Corporation, an initiate for chemical pleurodesis solutions, today announced that the U.S. Food and Drug Administration approved its product, Sterile Talc Powder (5 g, 100 ml vial), NDC 63256-200-04, administered intrapleurally via chest tube, as ... December 16, 2003; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Bryan Corporation Announces FDA Approval of Sterile Talc Powder for the Treatment of Malignant Pleural Effusion Pleurodesis Via Chest Tube Administration.
|
